| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 151, Issue 3 1548-1561, Copyright © 1993 by American Association of Immunologists
ARTICLES |
KM Mohler, DS Torrance, CA Smith, RG Goodwin, KE Stremler, VP Fung, H Madani and MB Widmer
Department of Immunology, Immunex Corporation, Seattle, WA 98101.
Two forms (monomeric or dimeric) of the extracellular, ligand-binding portion of the human p80 cell-surface receptor for TNF were used to antagonize TNF activity in vitro and in vivo. The dimeric sTNFR:Fc molecule was a more potent inhibitor of TNF than the monomeric sTNFR (50 to 1000x), as assessed in vitro by inhibition of TNF binding or bioactivity and in vivo by protection of mice from an otherwise lethal injection of LPS. Surprisingly, the dimeric sTNFR:Fc construct demonstrated a beneficial effect even when administered 3 h after a lethal LPS injection (i.e., after serum TNF levels had peaked and receded). To study the mechanism by which the soluble TNFR functions in vivo, serum TNF levels were examined in mice given LPS in the presence or absence of soluble receptor. Administration of a mortality-reducing dose of sTNFR:Fc ablated the rise in serum TNF bioactivity that normally occurs in response to LPS. However, TNF bioactivity was revealed in these "TNF-negative" serum samples when the L929 bioassay was modified by inclusion of a mAb that blocks the binding of murine TNF to the human soluble TNFReceptor. These results indicate that the absence of direct cytolytic activity in the L929 assay was caused by neutralization of TNF, rather than to an absence of TNF in the serum. Moreover, administration of either monomeric sTNFR or low doses of dimeric sTNFR:Fc actually resulted in increased serum TNF levels compared to mice given LPS but no soluble receptor. However, these "agonistic" doses of soluble receptor did not lead to increased mortality when an LD60 dose of LPS was given. Thus, dimeric sTNFR are effective inhibitors of TNF and under some circumstances function simultaneously as both TNF "carriers" and antagonists of TNF biologic activity.
This article has been cited by other articles:
|
|
 |
|
  G. Raghu, K. K. Brown, U. Costabel, V. Cottin, R. M. du Bois, J. A. Lasky, M. Thomeer, J. P. Utz, R. K. Khandker, L. McDermott, et al. Treatment of Idiopathic Pulmonary Fibrosis with Etanercept: An Exploratory, Placebo-controlled Trial Am. J. Respir. Crit. Care Med., November 1, 2008; 178(9): 948 - 955. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Holt, A. Basran, K. Jones, J. Chorlton, L. S. Jespers, N. D. Brewis, and I. M. Tomlinson Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs Protein Eng. Des. Sel., May 1, 2008; 21(5): 283 - 288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Chen, G. Bu, Y. Takei, K. Sakamoto, S. Ikematsu, T. Muramatsu, and K. Kadomatsu Midkine and LDL-receptor-related protein 1 contribute to the anchorage-independent cell growth of cancer cells J. Cell Sci., November 15, 2007; 120(22): 4009 - 4015. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. T. Stathopoulos, A. Kollintza, C. Moschos, I. Psallidas, T. P. Sherrill, E. N. Pitsinos, S. Vassiliou, M. Karatza, S. A. Papiris, D. Graf, et al. Tumor Necrosis Factor-{alpha} Promotes Malignant Pleural Effusion Cancer Res., October 15, 2007; 67(20): 9825 - 9834. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Faulkner, D. M. Altmann, S. Ellmerich, I. Huhtaniemi, G. Stamp, and S. Sriskandan Sexual Dimorphism in Superantigen Shock Involves Elevated TNF-{alpha} and TNF-{alpha} induced Hepatic Apoptosis Am. J. Respir. Crit. Care Med., September 1, 2007; 176(5): 473 - 482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lo, L. E. Bernstein, B. Canavan, M. Torriani, M. B. Jackson, R. S. Ahima, and S. K. Grinspoon Effects of TNF-{alpha} neutralization on adipocytokines and skeletal muscle adiposity in the metabolic syndrome Am J Physiol Endocrinol Metab, July 1, 2007; 293(1): E102 - E109. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Robertson, A. S. Care, and R. J. Skinner Interleukin 10 Regulates Inflammatory Cytokine Synthesis to Protect Against Lipopolysaccharide-Induced Abortion and Fetal Growth Restriction in Mice Biol Reprod, May 1, 2007; 76(5): 738 - 748. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Plater-Zyberk, L A B Joosten, M M A Helsen, J Hepp, P A Baeuerle, and W B van den Berg GM-CSF neutralisation suppresses inflammation and protects cartilage in acute streptococcal cell wall arthritis of mice Ann Rheum Dis, April 1, 2007; 66(4): 452 - 457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Stosic-Grujicic, I. Cvetkovic, K. Mangano, M. Fresta, D. Maksimovic-Ivanic, L. Harhaji, D. Popadic, M. Momcilovic, D. Miljkovic, J. Kim, et al. A Potent Immunomodulatory Compound, (S,R)-3-Phenyl-4,5-dihydro-5-isoxasole Acetic Acid, Prevents Spontaneous and Accelerated Forms of Autoimmune Diabetes in NOD Mice and Inhibits the Immunoinflammatory Diabetes Induced by Multiple Low Doses of Streptozotocin in CBA/H Mice J. Pharmacol. Exp. Ther., March 1, 2007; 320(3): 1038 - 1049. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Shoji-Hosaka, Y. Kobayashi, M. Wakitani, K. Uchida, R. Niwa, K. Nakamura, and K. Shitara Enhanced Fc-Dependent Cellular Cytotoxicity of Fc Fusion Proteins Derived from TNF Receptor II and LFA-3 by Fucose Removal from Asn-Linked Oligosaccharides J. Biochem., December 1, 2006; 140(6): 777 - 783. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D van der Heijde, J C Da Silva, M Dougados, P Geher, I van der Horst-Bruinsma, X Juanola, I Olivieri, F Raeman, L Settas, J Sieper, et al. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis Ann Rheum Dis, December 1, 2006; 65(12): 1572 - 1577. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. V. Ramana, A. A. Fadl, R. Tammali, A. B. M. Reddy, A. K. Chopra, and S. K. Srivastava Aldose Reductase Mediates the Lipopolysaccharide-induced Release of Inflammatory Mediators in RAW264.7 Murine Macrophages J. Biol. Chem., November 3, 2006; 281(44): 33019 - 33029. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B Combe, C Codreanu, U Fiocco, M Gaubitz, P P Geusens, T K Kvien, K Pavelka, P N Sambrook, J S Smolen, J Wajdula, et al. Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison Ann Rheum Dis, October 1, 2006; 65(10): 1357 - 1362. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Liepinsh, S. I. Grivennikov, K. D. Klarmann, M. A. Lagarkova, M. S. Drutskaya, S. J. Lockett, L. Tessarollo, M. McAuliffe, J. R. Keller, D. V. Kuprash, et al. Novel Lymphotoxin Alpha (LT{alpha}) Knockout Mice with Unperturbed Tumor Necrosis Factor Expression: Reassessing LT{alpha} Biological Functions. Mol. Cell. Biol., June 1, 2006; 26(11): 4214 - 4225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Fivenson and B. Mathes Treatment of generalized lichen planus with alefacept. Arch Dermatol, February 1, 2006; 142(2): 151 - 152. [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Nowlan, E. Drewe, H. Bulsara, N. Esposito, R. A. Robins, P. J. Tighe, R. J. Powell, and I. Todd Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A Rheumatology, January 1, 2006; 45(1): 31 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mpofu, F. Fatima, and R. J. Moots Anti-TNF-{alpha} therapies: they are all the same (aren't they?) Rheumatology, March 1, 2005; 44(3): 271 - 273. [Full Text] [PDF]
|
|
|
|
|
|
M. Jit, B. Henderson, M. Stevens, and R. M. Seymour TNF-{alpha} neutralization in cytokine-driven diseases: a mathematical model to account for therapeutic success in rheumatoid arthritis but therapeutic failure in systemic inflammatory response syndrome Rheumatology, March 1, 2005; 44(3): 323 - 331. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Cataisson, A. J. Pearson, S. Torgerson, S. A. Nedospasov, and S. H. Yuspa Protein Kinase C{alpha}-Mediated Chemotaxis of Neutrophils Requires NF-{kappa}B Activity but Is Independent of TNF{alpha} Signaling in Mouse Skin In Vivo J. Immunol., February 1, 2005; 174(3): 1686 - 1692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Dai, J. Guzman, B. Chen, and U. Costabel Production of Soluble Tumor Necrosis Factor Receptors and Tumor Necrosis Factor-{alpha} by Alveolar Macrophages in Sarcoidosis and Extrinsic Allergic Alveolitis Chest, January 1, 2005; 127(1): 251 - 256. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Giles and J. M. Bathon Serious Infections Associated with Anticytokine Therapies in the Rheumatic Diseases J Intensive Care Med, November 1, 2004; 19(6): 320 - 334. [Abstract] [PDF]
|
|
|
|
 |
|
 T. Bachetti, L. Comini, E. Pasini, and R. Ferrari Anti-cytokine therapy in chronic heart failure: new approaches and unmet promises Eur. Heart J. Suppl., November 1, 2004; 6(suppl_F): F16 - F21. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Thakur, R. P. Barrett, J. A. Hobden, and L. D. Hazlett Caspase-1 Inhibitor Reduces Severity of Pseudomonas aeruginosa Keratitis in Mice Invest. Ophthalmol. Vis. Sci., September 1, 2004; 45(9): 3177 - 3184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Zarkesh-Esfahani, A. G. Pockley, Z. Wu, P. G. Hellewell, A. P. Weetman, and R. J. M. Ross Leptin Indirectly Activates Human Neutrophils via Induction of TNF-{alpha} J. Immunol., February 1, 2004; 172(3): 1809 - 1814. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Bacot, P. Lenz, M. R. Frazier-Jessen, and G. M. Feldman Activation by prion peptide PrP106-126 induces a NF-{kappa}B-driven proinflammatory response in human monocyte-derived dendritic cells J. Leukoc. Biol., July 1, 2003; 74(1): 118 - 125. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Schafers, C. I. Svensson, C. Sommer, and L. S. Sorkin Tumor Necrosis Factor-alpha Induces Mechanical Allodynia after Spinal Nerve Ligation by Activation of p38 MAPK in Primary Sensory Neurons J. Neurosci., April 1, 2003; 23(7): 2517 - 2521. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Schafers, D. H. Lee, D. Brors, T. L. Yaksh, and L. S. Sorkin Increased Sensitivity of Injured and Adjacent Uninjured Rat Primary Sensory Neurons to Exogenous Tumor Necrosis Factor-alpha after Spinal Nerve Ligation J. Neurosci., April 1, 2003; 23(7): 3028 - 3038. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Pandey, G. Tuncman, G. S. Hotamisligil, and F. Samad Divergent Roles for p55 and p75 TNF-{alpha} Receptors in the Induction of Plasminogen Activator Inhibitor-1 Am. J. Pathol., March 1, 2003; 162(3): 933 - 941. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bas, T. K. Kvien, N. Buchs, T. Fulpius, and C. Gabay Lower level of synovial fluid interferon-{gamma} in HLA-B27-positive than in HLA-B27-negative patients with Chlamydia trachomatis reactive arthritis Rheumatology, March 1, 2003; 42(3): 461 - 467. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Schumann, K. Muhlen, A. K. Kiemer, A. M. Vollmar, and G. Tiegs Parenchymal, But Not Leukocyte, TNF Receptor 2 Mediates T Cell-Dependent Hepatitis in Mice J. Immunol., February 15, 2003; 170(4): 2129 - 2137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Sato, J. A. Keelan, and M. D. Mitchell Critical Paracrine Interactions Between TNF-{alpha} and IL-10 Regulate Lipopolysaccharide-Stimulated Human Choriodecidual Cytokine and Prostaglandin E2 Production J. Immunol., January 1, 2003; 170(1): 158 - 166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Q. Eichacker, C. Parent, A. Kalil, C. Esposito, X. Cui, S. M. Banks, E. P. Gerstenberger, Y. Fitz, R. L. Danner, and C. Natanson Risk and the Efficacy of Antiinflammatory Agents: Retrospective and Confirmatory Studies of Sepsis Am. J. Respir. Crit. Care Med., November 1, 2002; 166(9): 1197 - 1205. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G Chevrel, P Garnero, and P Miossec Addition of interleukin 1 (IL1) and IL17 soluble receptors to a tumour necrosis factor {alpha} soluble receptor more effectively reduces the production of IL6 and macrophage inhibitory protein-3{alpha} and increases that of collagen in an in vitro model of rheumatoid synoviocyte activation Ann Rheum Dis, August 1, 2002; 61(8): 730 - 733. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. N. Cunningham, H. M. Dyanov, P. Park, J. Wang, K. A. Newell, and R. J. Quigg Acute Renal Failure in Endotoxemia Is Caused by TNF Acting Directly on TNF Receptor-1 in Kidney J. Immunol., June 1, 2002; 168(11): 5817 - 5823. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Scallon, A. Cai, N. Solowski, A. Rosenberg, X.-Y. Song, D. Shealy, and C. Wagner Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists J. Pharmacol. Exp. Ther., May 1, 2002; 301(2): 418 - 426. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. A. Mabbott, G. McGovern, M. Jeffrey, and M. E. Bruce Temporary Blockade of the Tumor Necrosis Factor Receptor Signaling Pathway Impedes the Spread of Scrapie to the Brain J. Virol., April 16, 2002; 76(10): 5131 - 5139. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Chabaud, G. Page, and P. Miossec Enhancing Effect of IL-1, IL-17, and TNF-{alpha} on Macrophage Inflammatory Protein-3{alpha} Production in Rheumatoid Arthritis: Regulation by Soluble Receptors and Th2 Cytokines J. Immunol., November 15, 2001; 167(10): 6015 - 6020. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Gorak-Stolinska, J.-P. Truman, D. M. Kemeny, and A. Noble Activation-induced cell death of human T-cell subsets is mediated by Fas and granzyme B but is independent of TNF-{alpha} J. Leukoc. Biol., November 1, 2001; 70(5): 756 - 766. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. Bolger, R. Sharma, P. Aukrust, L. Gullestad, H. Aass, J. G. Fjeld, L. Wikeby, A. K. Andreassen, H. Ihlen, S. Simonsen, et al. Increase in Anti-Inflammatory Cytokine Levels in Chronic Heart Failure: A Measure of Treatment Success or Failure? Response Circulation, October 30, 2001; 104 (18): e97 - e97. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Carballo and P. J. Blackshear Roles of tumor necrosis factor-{alpha} receptor subtypes in the pathogenesis of the tristetraprolin-deficiency syndrome Blood, October 15, 2001; 98(8): 2389 - 2395. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Morita, M. Miura, D. R. Paolone, T. M. Engeman, A. Kapoor, D. G. Remick, and R. L. Fairchild Early Chemokine Cascades in Murine Cardiac Grafts Regulate T Cell Recruitment and Progression of Acute Allograft Rejection J. Immunol., September 1, 2001; 167(5): 2979 - 2984. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hattar, L. Fink, K. Fietzner, B. Himmel, F. Grimminger, W. Seeger, and U. Sibelius Cell Density Regulates Neutrophil IL-8 Synthesis: Role of IL-1 Receptor Antagonist and Soluble TNF Receptors J. Immunol., May 15, 2001; 166(10): 6287 - 6293. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kadokami, C. F. McTiernan, T. Kubota, C. S. Frye, G. S. Bounoutas, P. D. Robbins, S. C. Watkins, and A. M. Feldman Effects of soluble TNF receptor treatment on lipopolysaccharide-induced myocardial cytokine expression Am J Physiol Heart Circ Physiol, May 1, 2001; 280(5): H2281 - H2291. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Deswal, N. J. Petersen, A. M. Feldman, J. B. Young, B. G. White, and D. L. Mann Cytokines and Cytokine Receptors in Advanced Heart Failure : An Analysis of the Cytokine Database from the Vesnarinone Trial (VEST) Circulation, April 24, 2001; 103(16): 2055 - 2059. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. H.S. Choy and G. S. Panayi Cytokine Pathways and Joint Inflammation in Rheumatoid Arthritis N. Engl. J. Med., March 22, 2001; 344(12): 907 - 916. [Full Text] [PDF]
|
|
|
|
|
|
L Berg, J Lampa, S Rogberg, R van Vollenhoven, and L Klareskog Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNF{alpha} receptors Ann Rheum Dis, February 1, 2001; 60(2): 133 - 139. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. R. Cooke, G. R. Hill, A. Gerbitz, L. Kobzik, T. R. Martin, J. M. Crawford, J. P. Brewer, and J. L. M. Ferrara Hyporesponsiveness of Donor Cells to Lipopolysaccharide Stimulation Reduces the Severity of Experimental Idiopathic Pneumonia Syndrome: Potential Role for a Gut-Lung Axis of Inflammation J. Immunol., December 1, 2000; 165(11): 6612 - 6619. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Jin, D. P. Raymond, T. D. Crabtree, S. J. Pelletier, C. W. Houlgrave, T. L. Pruett, and R. G. Sawyer Enhanced Murine Macrophage TNF Receptor Shedding by Cytosine-Guanine Sequences in Oligodeoxynucleotides J. Immunol., November 1, 2000; 165(9): 5153 - 5160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Spencer-Green Etanercept (Enbrel): update on therapeutic use Ann Rheum Dis, November 1, 2000; 59(90001): i46 - 49. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. W Selmaj Tumour necrosis factor and anti-tumour necrosis factor approach to inflammatory demyelinating diseases of the central nervous system Ann Rheum Dis, November 1, 2000; 59(90001): i94 - 102. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Koga, Y. Osuga, O. Tsutsumi, R. Okagaki, M. Momoeda, T. Yano, T. Fujiwara, Y. Takai, K. Kugu, Y. Morita, et al. Increased concentrations of soluble tumour necrosis factor receptor (sTNFR) I and II in peritoneal fluid from women with endometriosis Mol. Hum. Reprod., October 1, 2000; 6(10): 929 - 933. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-M. Coelho, J. Fioramonti, and L. Bueno Systemic lipopolysaccharide influences rectal sensitivity in rats: role of mast cells, cytokines, and vagus nerve Am J Physiol Gastrointest Liver Physiol, October 1, 2000; 279(4): G781 - G790. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Mohler, K. M. Murray, D. L. Mann, and G. Francis Use of Targeted Anticytokine Treatments in Heart Failure Circulation, August 29, 2000; 102 (9): e65 - e65. [Full Text] [PDF]
|
|
|
|
|
|
T. Kubota, G. S. Bounoutas, M. Miyagishima, T. Kadokami, V. J. Sanders, C. Bruton, P. D. Robbins, C. F. McTiernan, and A. M. Feldman Soluble Tumor Necrosis Factor Receptor Abrogates Myocardial Inflammation but Not Hypertrophy in Cytokine-Induced Cardiomyopathy Circulation, May 30, 2000; 101(21): 2518 - 2525. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Opal and V. A. DePalo Anti-Inflammatory Cytokines Chest, April 1, 2000; 117(4): 1162 - 1172. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Lovell, E. H. Giannini, A. Reiff, G. D. Cawkwell, E. D. Silverman, J. J. Nocton, L. D. Stein, A. Gedalia, N. T. Ilowite, C. A. Wallace, et al. Etanercept in Children with Polyarticular Juvenile Rheumatoid Arthritis N. Engl. J. Med., March 16, 2000; 342(11): 763 - 769. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Fox Cytokine Blockade as a New Strategy to Treat Rheumatoid Arthritis: Inhibition of Tumor Necrosis Factor Arch Intern Med, February 28, 2000; 160(4): 437 - 444. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Truyens, F. Torrico, R. Lucas, P. De Baetselier, W. A. Buurman, and Y. Carlier The Endogenous Balance of Soluble Tumor Necrosis Factor Receptors and Tumor Necrosis Factor Modulates Cachexia and Mortality in Mice Acutely Infected with Trypanosoma cruzi Infect. Immun., November 1, 1999; 67(11): 5579 - 5586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Quattrocchi, M. Walmsley, K. Browne, R. O. Williams, L. Marinova-Mutafchieva, W. Buurman, D. M. Butler, and M. Feldmann Paradoxical Effects of Adenovirus-Mediated Blockade of TNF Activity in Murine Collagen-Induced Arthritis J. Immunol., July 15, 1999; 163(2): 1000 - 1009. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
